reports
- Hilde Van Boxstael
- Jacob Mekhael
- Sharad Kumar S.P
- Thomas Couvreur
- Thomas Vranken
- Wim Lewi
- Jacob Mekhael
Galapagos FIRST LOOK: Presents positive updated CAR-T results in r/r N...
Galapagos presented updated results from the phase 1/2 (ATLANTA-1) trial of GLPG5101 (CD19 CAR-T) in r/r NHL (non-Hodgkin's lymphoma) at EHA, which continue to show solid outcomes in line with Yescarta (CD19 CAR-T, Gilead), while the FL cohort stands out for its high CR rate. With >30 patients, the dataset is beginning to mature, de-risking the CAR-T program in r/r NHL, and we look forward to IND submission in the US in mid-2024 to unlock the next stage of development. We reiterate our € 50 TP a...
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5...
Galapagos presents encouraging new data for CD19 CAR-T candidate GLPG5101 in non-Hodgkin lymphoma at EHA 2024 Mechelen, Belgium; June 14, 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced that it will present encouraging new data from the ongoing Phase 1/2 ATALANTA-1 study of CD19 CAR-T candidate, GLPG5101, in relapsed/refractory non-Hodgkin lymphoma (R/R NHL) at the annual European Hematology Association (EHA) 2024 Hybrid Congress. Galapagos' product candidate GLPG5101 is produced using the company's innovative, decentralized T-cell manufacturing platform. The oral p...
Galapagos presenteert bemoedigende nieuwe resultaten voor CD19 CAR-T k...
Galapagos presenteert bemoedigende nieuwe resultaten voor CD19 CAR-T kandidaat GLPG5101 in non-Hodgkin lymfoom op EHA 2024 Mechelen, België; 14 juni 2024, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) kondigde vandaag aan dat het bemoedigende nieuwe resultaten zal presenteren van de lopende fase 1/2 ATALANTA-1 studie van CD19 CAR-T kandidaat, GLPG5101, in recidief/refractair non-Hodgkin lymfoom (R/R NHL) op het jaarlijkse European Hematology Association (EHA) 2024 hybride congres. Galapagos' productkandidaat GLPG5101 wordt geproduceerd met behulp van het innovatieve, gedecentraliseerde ...
- Jacob Mekhael
- Thomas Vranken
Fugro N.V.: 1 director
A director at Fugro N.V. sold 1,294 shares at 23.790EUR and the significance rating of the trade was 52/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showi...
- Jacob Mekhael
Galapagos Gets the BD ball rolling with option on Adaptimmune's uza-ce...
Galapagos and Adaptimmune have entered into a clinical collaboration agreement with an option to exclusively license Adaptimmune's uza-cel (TCR-T cell therapy targeting MAGE-A4) for head & neck cancer and potential future solid tumour indications, using Galapagos' decentralised cell manufacturing platform for an $ 70m upfront, $ 30m in R&D funding, as well as an option exercise fee of $ 100m, plus $ 465m in milestones, and tiered mid-single to low-double digit royalties. We welcome this deal whi...
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Thomas Vranken
- Wim Hoste
- Wim Lewi
- David Seynnaeve
- PhD
Galapagos - Collaboration agreement with Adaptimmune
New clinical collaboration agreement with an option to exclusively license Adaptimmune's next-generation TCR T-cell therapy (uza-cel) for head & neck cancer and potential future solid tumor indications. Galapagos will pay USD 100m upfront.Initial in vitro results suggest that uza-cel, produced on Galapagos' decentralized manufacturing platform, yields early phenotype T-cells that could improve efficacy and durability compared to uza-cel centrally manufactured on Adaptimmune's plat...
Galapagos and Adaptimmune sign clinical collaboration agreement with a...
Galapagos and Adaptimmune sign clinical collaboration agreement with an option to exclusively license Adaptimmune’s TCR T-cell therapy candidate, uza-cel, in head & neck cancer and potential future solid tumor indications Adaptimmune and Galapagos to conduct clinical proof-of-concept trial to evaluate the safety and efficacy of uza-cel (next generation MAGE-A4 TCR T-cell therapy) produced on Galapagos’ decentralized manufacturing platform in patients with head & neck cancerUza-cel has shown encouraging results in head & neck cancer with partial responses in four out of five patients to date...
Galapagos en Adaptimmune ondertekenen klinische samenwerkingsovereenko...
Galapagos en Adaptimmune ondertekenen klinische samenwerkingsovereenkomst met optie om Adaptimmune's TCR T-celtherapiekandidaat, uza-cel, exclusief in te licentiëren voor hoofd- & halskanker en mogelijke toekomstige vaste tumoren indicaties Adaptimmune en Galapagos zullen een klinische proof-of-concept studie uitvoeren om de veiligheid en werkzaamheid te evalueren van uza-cel (nieuwe generatie MAGE-A4 TCR T-celtherapie) geproduceerd op het gedecentraliseerde productieplatform van Galapagos bij patiënten met hoofd- en halskankerUza-cel heeft bemoedigende resultaten laten zien bij hoofd- en h...
- Guy Sips
Miko Receiving earn-out of € 5m from the sale of Miko Pac in 2021
Miko announced that it received an earn-out of € 5m on the 2021 sale of its plastics processing division Miko Pac, which was sold to Paccor (Germany). This positive news came after the negative news last Friday when Miko announced - a little to our surprise - that it has sold subsidiary ‘SAS Koffie' (Beerse, Belgium) to a Dutch investment company and to return to its core business. Miko stated that this transaction does involve a significant accounting impairment and also one-time costs, which w...
- Guy Sips
Galapagos creëert nieuwe inschrijvingsrechtenplannen
Galapagos creëert nieuwe inschrijvingsrechtenplannen Mechelen, België; 16 mei 2024; 22:01 CET ; gereglementeerde informatie – Galapagos NV (Euronext & NASDAQ: GLPG) kondigt vandaag aan dat haar Raad van Bestuur 1.614.000 inschrijvingsrechten heeft gecreëerd onder nieuwe inschrijvingsrechtenplannen ten gunste van bepaalde leden van het personeel van de vennootschap en haar dochtervennootschappen. De Raad van Bestuur van Galapagos heeft op 16 mei 2024 “Inschrijvingsrechtenplan 2024 BE”, bestemd voor de personeelsleden van de vennootschap, “Inschrijvingsrechtenplan 2024 RMV”, bestemd voor d...
Galapagos creates new subscription right plans
Galapagos creates new subscription right plans Mechelen, Belgium; 16 May 2024, 22:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) announced today that its Board of Directors created 1,614,000 subscription rights under new subscription right plans for the benefit of certain members of the personnel of the company and its subsidiaries. On 16 May 2024, the Board of Directors of Galapagos approved “Subscription Right Plan 2024 BE”, intended for members of personnel of the company, “Subscription Right Plan 2024 RMV,” intended for the employees of its French subsidiary, Ga...
- Jan Frederik Slijkerman
Liberty Global operating companies/1Q24 Earnings: UPCB, TNETBB, ZIGGO ...
The 1Q24 earnings reports of the four high yield telecom companies that are (partially) owned by Liberty Global were mixed. 1Q24 adj. EBITDA performance was strong at VodafoneZiggo and Sunrise, while it was soft at Telenet and Virgin Media O2. We prefer to own Sunrise and Ziggo, today. Given similar credit profiles and the same (partial) owner at the moment, Liberty Global, we expect limited spread dispersion across the group. The main challenge to this view is our idea that we expect that Liber...
- Hilde Van Boxstael
- Jacob Mekhael
- Lynn Hautekeete
- Sharad Kumar S.P
- Thomas Couvreur
- Wim Hoste
- Wim Lewi
- Jacob Mekhael
Galapagos Unlocks scalability potential of POC CAR-Ts with BCA US coll...
Galapagos announced a collaboration with Blood Centers of America (BCA), gaining access to BCA's network of >50 sites in the US for the decentralised manufacturing (POC) of Galapagos' CAR-T cell therapies (financial details not disclosed). We believe this collaboration could unlock significant manufacturing capacity for Galapagos in the US, and our back of the envelope calculation points to a capacity of 8K CAR-Ts per year with just 4 Cocoon's in each site – this comes close to Gilead's 2024 glo...
Galapagos and Blood Centers of America announce strategic collaboratio...
Galapagos and Blood Centers of America announce strategic collaboration to accelerate Galapagos’ decentralized CAR-T manufacturing network in the U.S. BCA's national network of blood centers will provide decentralized manufacturing services for Galapagos' CAR-T product candidates, close to cancer treatment centersCollaboration enables rapid deployment of Galapagos' decentralized CAR-T platform across the U.S., improving patient access to potentially life-saving CAR-T treatmentsImportant milestone for Galapagos' U.S. expansion strategy, supporting upcoming pivotal trials and potential future...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.